The US Food and Drug Administration (FDA) has approved the citrate-free, high-concentration (100mg/mL) formulation of Hadlima (adalimumab-bwwd), a biosimilar referencing AbbVie’s (NYSE: ABBV) mega-blockbuster Humira (adalimumab). Hadlima was developed by South Korea-based Samsung Bioepis and will be commercialized by Organon (NYSE: OGN).
Hadlima will be available in pre-filled syringe and autoinjector options, and the autoinjector was specifically designed with the patient in mind. Hadlima was previously approved by the FDA as a low-concentration (50mg/mL) formulation in July 2019 and outside the USA that formulation has been available in various markets globally under different brand names, with over 5 million doses sold since 2018.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze